Arbutus Biopharma Corp
Arbutus Biopharma develops treatments for chronic hepatitis B infection, including imdusiran (AB-729) and an oral PD-L1 inhibitor (AB-101), both in clinical stage.
SCHEDULE 13GSep 4Latest SEC filing
Aug 21Latest story
Sign inSign inArbutus Biopharma develops treatments for chronic hepatitis B infection, including imdusiran (AB-729) and an oral PD-L1 inhibitor (AB-101), both in clinical stage.